Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Intravenously Administered KT-333 in Adult Patients With Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia, and Solid Tumors

Next Previous
X
Search
Trial Profile

A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Intravenously Administered KT-333 in Adult Patients With Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia, and Solid Tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Aug 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs KT-333 (Primary)
  • Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Cutaneous T-cell lymphoma; Haematological malignancies; Large granular lymphocytic leukaemia; Lymphoma; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma; Solid tumours; T-cell lymphoma
  • Focus Adverse reactions; Proof of concept
  • Sponsors Kymera Therapeutics

    • Most Recent Events

    • 07 Aug 2024 According to a Kymera Therapeutics media release, the Company expects to complete enrollment of the Phase 1a trial and share data in the second half of 2024.
    • 14 Jun 2024 Results presented in the Kymera Therapeutics Media Release.
    • 14 Jun 2024 According to a Kymera Therapeutics media release, as of June 3, 2024 trial enrolled 47 patients. The Company expects to complete the study and share additional clinical data to inform the program's next development steps in 2024 at an upcoming medical meeting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top